FORTUNE — On Jan. 23, the FDA dropped a heavy hammer on the Indian
generic drug giant Ranbaxy Laboratories, announcing it will restrict imports from the company's manufacturing plant in Toansa, India.
Generic drug giant Teva really is going to cut tens of thousands of jobs in a gigantic restructure for the struggling and debt - laden pharmaceutical — in fact, the 14,000 planned layoffs announced Thursday actually surpass initial reports.
Here's how it went: Shortly before 9 a.m. New York time (and before U.S. markets opened),
generic drug giant Teva Pharmaceutical (TEVA) confirmed its unwelcome bid to acquire rival Mylan (MYL) for $ 40 billion.
Generic drug giant Mylan is cutting its financial outlook as it continues to face pressure from falling generic drug prices (a fate that similarly struck rival Teva Pharmaceuticals).
Not exact matches
Early rumors that British pharma
giant AstraZeneca's chief executive, Pascal Soriot, was considering jumping ship to the major (and troubled)
generic drug manufacturer Teva sent the biopharma world into a tizzy.
While pharmaceutical
giant Pfizer is trying to get the Supreme Court of Canada to take a second look at its recent judgment voiding its patent on Viagra, it's trying to use the same decision to quash a case in the Federal Court involving another
generic drug maker.